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https://doi.org/10tudy Objective: Patients who have undergone endometrial ablation may present a diagnostic challenge when they subse-
quently develop vaginal bleeding, pelvic pain, or postmenopausal bleeding. Extensive scarring of the uterine cavity often
precludes evaluation and/or conservative treatment. For further research on this topic, we performed hysteroscopic examina-
tion in study subjects a mean duration of 4 years after they had undergone water vapor endometrial ablation.
Design: Prospective, multicenter, observational clinical study.
Setting: Eight private practice or outpatient sites in the United States and Mexico.
Patients: Seventy subjects who had completed their 36-month follow-up in the AEGEA Pivotal Trial.
Interventions: Diagnostic hysteroscopy.
Measurements and Main Results: The subjects were screened for general health and infection and underwent diagnostic
hysteroscopy. Menstrual bleeding status was recorded. The video of the hysteroscopic examination was analyzed by an
independent reviewer, who assessed uterine cavity access and visualization of the cornua and tubal ostia as well as charac-
terized adhesions on the basis of the criteria by March et al. An independent reviewer also subjectively assessed whether
Pipelle endometrial biopsy or intrauterine device placement would be feasible. Uterine cavity access was achieved in 90%
(63/70) of subjects. Among subjects with cavity access, the cornua and ostia were visualized in 79% (50/63) and adhesions
were absent in 75% (47/63), with only 2 women having severe adhesions (3%, 2/63). Biopsy was projected to be feasible in
86% (62/70) and intrauterine device placement in 60% (42/70) of all subjects. The subjects’ bleeding statuses were not cor-
related with uterine cavity access. The results were consistent for subjects with large uterine cavities and International Fed-
eration of Gynecologic and Obstetrics type II to VI myomas ≤4 cm.
Conclusion: Water vapor endometrial ablation preserved an accessible uterine cavity and visualization of the ostia in most
subjects, with minimal incidence of severe adhesions, a mean of 4 years after the ablation procedure. Journal of Minimally
Invasive Gynecology (2020) 27, 1273−1280. © 2019 AAGL. This is an open access article under the CC BY-NC-ND
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.1016/j.jmig.2019.09.775Endometrial ablation is a minimally invasive treatment
for heavy menstrual bleeding due to benign causes (primar-
ily, abnormal uterine bleeding-endometrial, AUB-E) in
women who have completed childbearing. With the
increase in the use of endometrial ablation, potential issues
associated with it have become commonplace, with issues
often manifesting many years after the original treatment.
Recurrent heavy bleeding, cyclic pelvic pain with or with-
out bleeding, and postmenopausal bleeding may occur and
require uterine cavity evaluation, ideally using hysteros-
copy or endometrial biopsy.
The treatment of patients presenting with these symp-
toms can be challenging for a gynecologist and may lead to-
1274 Journal of Minimally Invasive Gynecology. Vol 27, No 6, September/October 2020situations in which the patients are subjected to hysterec-
tomy because the uterine cavity can be neither accessed nor
evaluated. A lack of uterine cavity access because of the
formation of adhesions after ablation has been observed
and documented as a long-term sequela of endometrial
ablation [1]. If long-term access to the uterine cavity after
endometrial ablation were possible, less invasive diagnostic
or therapeutic interventions could be offered.
Water vapor ablation (AEGEA Medical, Menlo Park,
CA) is a U.S. Food and Drug Administrationapproved
endometrial ablation technique that uses rapid energy
transfer of water vapor as it changes from the vapor state
to liquid droplets. Water vapor fills the uterine cavity,
regardless of its shape or configuration, and transfers
energy onto the exterior of the cell membranes. With con-
densation from gas to liquid, energy is released, which in
turn produces the desired tissue effect [2]. Post-treatment
histologic studies of the endometrium and myometrium in
subjects who had undergone water vapor ablation revealed
no carbonization or heat fixation of tissue [3,4]. Further-
more, the conforming nature of water vapor allowed the
inclusion of this technique in the pivotal clinical trial of
subjects with uterine cavity lengths of up to 12 cm and
nonobstructing International Federation of Gynecologic
and Obstetrics (FIGO) type II to VI leiomyomata ≤4 cm
[2]. Subjects with uterine septa less than one-third the cav-
ity length and Essure contraceptive tubal inserts (Bayer
Corporation, Whippany, NJ) were not excluded from the
pivotal trial. This Post-Ablation Cavity Evaluation
(PACE) study was designed to evaluate long-term hystero-
scopic uterine cavity access after water vapor ablation in a
cohort comprising subjects who had completed 36 months
of follow-up in the pivotal trial.Fig. 1
Subject disposition. PACE = Post-Ablation Cavity Evaluation.
Subjects exing 36-month Pivotal 
Trial and eligible for parcipaon
N = 125
Subjects exing study
N = 72
Hysteroscopy performed
N = 72
Data reported N = 70
Subjects screened for parcipaon in 
PACE study
N = 72Materials and Methods
A prospective, multicenter, single-arm, observational
study to evaluate postablation uterine cavity access was
conducted at 8 study centers in the United States and Mex-
ico from September 2018 to March 2019. The first study
cohort was evaluated at 7 sites in the United States and the
second at 1 site in Mexico. The protocol for both cohorts
involved the same inclusion and exclusion criteria, hystero-
scopic assessment, and observational end points. The study
comprised a screening visit, diagnostic hysteroscopy, and
follow-up phone call on day 7 to assess safety.
The study was conducted in accordance with Good Clin-
ical Practice guidelines, as contained in the International
Conference on Harmonization and US Code of Federal
Regulations, and in accordance with the Declaration of Hel-
sinki. The study protocol was approved by both central and
local institutional review boards (IRBs) (Copernicus Group,
Western IRB, Mercy Hospital IRB, Baylor Scott & White
Research Institute IRB, and the Research Committee of the
Universidad Autonoma de Nuevo Leon). Written informed
consent was obtained from all subjects for study participa-
tion, which included consent for still and video imaging of
the hysteroscopic examination.
Women who were eligible for enrollment had completed
their 36-month follow-up in the AEGEA Pivotal Clinical
Trial (NCT01979861). Fig. 1 presents the subject disposi-
tion flow diagram. The water vapor ablation procedures
were conducted between May 2014 and May 2015. The
subjects were also required to have had normal Pap smear
test results within the past 5 years.
Subjects were excluded from participation if they had
undergone a repeat endometrial ablation, insertion of anExcluded from analysis:
1. Prior polypectomy
2. Video file corrupted
Subjects not 
available or declined
N = 53
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dure involving the application of an energy source or distur-
bance of endometrial tissue. Exclusion criteria also
included pregnancy, as determined by a urine pregnancy
test; evidence of an active sexually transmitted infection;
active genitourinary tract infection; or suspected or con-
firmed gynecologic malignancy within the last 5 years. Of
the 72 subjects who consented to study participation, 2
were excluded from the analysis: one because of a protocol
violation as polypectomy and adhesiolysis had been per-
formed before enrollment in the PACE protocol and the
other because of a corrupt hysteroscopy video file, resulting
in missing data for independent review. All enrolled sub-
jects completed the 1-week follow-up.
The primary observational end point was the ability to
access the uterine cavity and perform a diagnostic hystero-
scopic examination. Other observational end points
included the following: the ability to visualize the uterine
cornua and tubal ostia and the presence and characterization
of adhesions within the endometrial cavity. Finally, on the
basis of a review of the hysteroscopy videos, the indepen-
dent reviewer made a subjective assessment of the feasibil-
ity of Pipelle endometrial biopsy and IUD placement. The
subjects’ menstrual status was also recorded. Data were
expressed as mean § SD.
The safety end points were an assessment of diagnostic
hysteroscopy−related serious adverse events and the overall
rate and severity of all reported gynecologic adverse events.
Each investigator was a gynecologist with experience in
performing hysteroscopy and endometrial ablation. All hys-
teroscopies were conducted in an office or outpatient setting
using commercially available equipment. The selection of
the hysteroscope and distension medium was at the discre-
tion of the investigator. Hysteroscopy videos and still
images were acquired in a standardized manner per estab-
lished guidelines, which included instructions for careful
video recording, beginning with entrance into the external
cervical ostium. This allowed complete video documenta-
tion of adhesions from the cervical ostia to the uterine cav-
ity. Lysis of adhesions was not allowed per the protocol.
Digital copies of the hysteroscopic images and videos
were transferred to a core laboratory where a quality-control
check was conducted. To ensure consistency and objectivity
in image interpretation across all study sites, an experienced
independent clinician, “independent reviewer,” blinded to
pivotal trial and ablation procedure data, evaluated theTable 1
Adhesion criteria
Category Criteria
Minimal Less than one-fourth of uterine cavity, and thin or filmy adhe
Moderate One-fourth to three-fourths of uterine cavity, with no agglutin
Severe More than three-fourths of uterine cavity, or agglutination ofsubmitted videos according to the observational end points.
The independent reviewer characterized uterine cavity adhe-
sions as minimal, moderate, or severe according to the adhe-
sion criteria by March et al [5], as shown in Table 1. An
adhesion was defined as adherence of the uterine walls to
each other, creating a bridge or band spanning the uterine
cavity. Biopsy specimens were not collected and IUDs were
not placed as part of this observational clinical study, but the
independent reviewer subjectively projected whether these
interventions were feasible.
In this study, categorical data were summarized using fre-
quency tables, with numbers and percentages of subjects. For
continuous variables, descriptive statistics included the number
of subjects (n), mean, SD, median, minimum, and maximum.
In addition, selection bias analysis was performed by an
independent biostatistician (P.S.) to assess the comparabil-
ity of the subjects enrolled in this study with the remaining
eligible subjects who had completed their 36-month follow-
up in the pivotal water vapor ablation study. A total of 126
subjects had completed their 36-month follow-up in the
AEGEA Pivotal Trial. The PACE study enrolled 72 of these
subjects. To evaluate selection bias, the characteristics of
the 72 subjects who consented to participate in the PACE
study were analyzed and compared with those of the
remaining 54 subjects who had completed the pivotal trial.
The following variables were assessed: demographics, site
of service and analgesia used for the original procedure,
and pain after the ablation procedure. Comparative analyses
also included the following pivotal trial assessments at
baseline and 12, 24, and 36 months: bleeding; quality of
life, as measured by the Menorrhagia Impact Questionnaire;
and treatment satisfaction.Results
Subject Demographics and Gynecologic History
The mean age of the subjects was 43§ 5 years (range 33−
54). The mean body mass index of the subjects was 29.9 §
7.0 kg/m2 (range 17−51). Regarding race, 96% (67/70)
chose white, and regarding ethnicity, 30% (21/70) listed
Hispanic or Latino. For this cohort of PACE subjects, the
mean pivotal trial baseline Pictorial Blood Loss Assessment
Chart (by Higham et al [6]) score was 323.9 § 146.2, and at
the 12-month follow-up, it was 24.7 § 38.2. The menstrual
status data from the 24- and 36-month follow-up in thesions, and ostial areas and upper fundus minimally involved or clear
ation of walls, and ostial areas and upper fundus only partially occluded
walls or thick bands, or ostial area and upper cavity occluded
Fig. 2
Mean percentage of subject’s reported menstrual status at 12, 24, and 36 months postablation and PACE baseline with cavity access. PACE = Post-Abla-
tion Cavity Evaluation.
1276 Journal of Minimally Invasive Gynecology. Vol 27, No 6, September/October 2020pivotal trial, as well as from PACE baseline, show consis-
tency of the menstrual pattern across these time points
(Fig. 2). At PACE baseline, 93% (65/70) of subjects
reported normal or no menstrual bleeding. The mean dura-
tion from the water vapor endometrial ablation procedure
in the pivotal trial to the date of diagnostic hysteroscopy in
the PACE study was 3.9 § 0.3 (range 3.4−4.4) years.Diagnostic Hysteroscopy Procedure
In most cases (66/70, 94%), diagnostic hysteroscopy was
performed with a rigid hysteroscope. The hysteroscope’s
outer diameter ranged from 3 to 6 mm. Normal saline
(0.9%) was used as the distension medium in all cases.Primary Observational End Point
Uterine cavity access by hysteroscopy was achieved in
90% (63/70) of subjects. Access was limited to the endocer-
vical canal in the remaining 7 subjects (10%). The cornua
and ostia were visualized in 79% (50/63) of cavities
accessed or 71% (50/70) of all subjects, with 60% (30/50)
bilateral and 40% (20/50) unilateral visualization of the cor-
nua and ostium. Representative photographs of uterine cav-
ities with visualization of both the cornua and the ostia,
with access but no visualization of the cornua, and with
only endocervical access are shown in Fig. 3.
Adhesions were absent in 75% (47/63) of uterine cavities
that were accessed. Adhesions were characterized as “minimal”
in 11% (7/63), “moderate” in 11% (7/63), and “severe” in 3%
(2/63) of subjects. No data regarding the severity of intrauterineadhesions could be obtained from the 7 subjects in whom cavity
access was not possible. The independent reviewer subjectively
determined that endometrial biopsy would be feasible in 89%
(62/70) of subjects and that successful IUD placement would
be feasible in 60% (42/70) of subjects. In one of the 2 subjects
who had severe adhesions, the cavity was considered accessible,
but the reviewer reprted that representative biopsy would not be
feasible due to the adhesions.Menstrual Status
Analysis of the potential correlation between cavity
access and menstrual status was carried out on the basis of
subject-reported menstrual status (none, light, moderate,
heavy, or very heavy bleeding) at the time of study screen-
ing. Menstrual bleeding was further stratified by cavity
access, with or without visualization of 1 or both cornua.
As shown in Table 2 and Fig. 4, cavity access was achieved
in 89% (17/19) of subjects with amenorrhea, 87% (27/31)
of subjects with light bleeding, 100% (15/15) of subjects
with moderate bleeding, and 80% (4/5) of subjects with
heavy or very heavy bleeding. Spearman’s rank correlation
coefficient was 0.19 (95% confidence interval −0.05 to
0.4), indicating no correlation between menstrual bleeding
status and hysteroscopic access to the uterine cavity.Cavity Access and Menstrual Status in Subpopulations
Of the 70 subjects evaluated, 29 (41%) had large uterine
cavities (10−12-cm uterine cavity lengths), FIGO type II to
VI non−cavity-obstructing myomas ≤4 cm in diameter,
Fig. 3
Long-term uterine cavity access. (a and b) Visualization of both cornua and ostia in the same subject; (c) Cavity access, no visualization of cornua; and
(d) Endocervical access only. Right and left cornua (arrows).
a b
c d
Table 2
Menstrual bleeding status and long-term cavity access
Bleeding status Amenorrhea
(n = 19)
Light
(n = 31)
Moderate
(n = 15)
Heavy/very heavy
(n = 5)
Total
(N = 70)
Uterine cavity access 17 (89) 27 (87) 15 (100) 4 (80) 63 (90)
Values are presented as n (%).
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large cavities, 11 had myomas, 3 had intratubal contracep-
tive inserts, and 3 had both large cavities and myomas.
These subpopulations are traditionally not indicated for
endometrial ablation treatment. Cavity access was achieved
in 90% (26/29) of these subjects. Visualization of the cor-
nua and ostia in the accessed cavities was 88% (23/26). In
addition, at the time of baseline screening for the PACE
study, 93% (27/29) of these subjects reported normal (mod-
erate), light, or no menstrual bleeding.Safety Results
No hysteroscopy-related serious adverse events were
reported. Of 72 subjects, 6 (8%) developed 1 or more gyne-
cologic adverse events. Only 1 gynecologic adverse event
(dysmenorrhea) was reported as “severe”; this resolved in
2 days with no intervention. The remaining adverse events
were pain, nausea, uterine cramping, and/or vaginal spotting.Analysis of Selection Bias
No clinically relevant differences were detected between
subjects enrolled in this study and eligible subjects who
completed the pivotal trial. Bleeding assessments of the
subjects in the 2 populations were nearly equivalent, with
94% (68/72) reporting normal bleeding or less in the PACE
cohort and 94% (51/54) in the non-PACE cohort at 36-
month follow-up assessment of the pivotal study. The entire
comparative cohort analysis is presented in Table 3.Discussion
Recurrent heavy bleeding, cyclic pain, and postmeno-
pausal bleeding may be associated with residual or regener-
ated endometrium, endometrial hyperplasia, endometrial
cancer, and/or adhesions that commonly present after
undergoing endometrial ablation. In separate prospective,
longitudinal, clinical trials, Taskin et al [7] and Onoglu et al
Fig. 4
Bleeding status and long-term cavity access.
Table 3
Selection bias analysis
Variable comparisons PACE
(N = 72)
Non-PACE
(N = 54)
Mean age at pivotal baseline (yrs) 39.5 40.6
Race, n (%)
White 69 (96) 51 (94)
Black 2 (3) 2 (4)
Asian 1 (1) 1 (2)
Mean BMI at pivotal baseline (kg/m2) 29.5 29.3
Mean gravidity at pivotal baseline 3.3 3.1
Mean parity at pivotal baseline 2.8 2.6
Mean uterine length at pivotal baseline (cm) 9.1 8.9
Dysmenorrhea at pivotal baseline, n (%) 56 (78) 49 (91)
Mean PBLAC at pivotal baseline 320.7 300.0
Mean PBLAC at pivotal 12-month 25.2 39.6
Menstrual status of normal bleeding
or less at pivotal 36-month, n (%)
68 (94) 51 (94)
Mean MIQ at pivotal baseline 14.8 14.5
Mean MIQ at pivotal 36-month 6.2 6.4
Patient satisfaction at pivotal 36-month, n (%) 65 (90) 50 (93)
BMI = body mass index; MIQ =Menorrhagia Impact Questionnaire;
PACE = Post-Ablation Cavity Evaluation; PBLAC = Pictorial Blood Loss
Assessment Chart.
1278 Journal of Minimally Invasive Gynecology. Vol 27, No 6, September/October 2020[8] performed hysteroscopy in a total of 71 women at least
30 months after endometrial ablation with either hystero-
scopic resection or rollerball ablation. A prominent finding
at the time of hysteroscopy in both studies was focal endo-
metrial regeneration. They concluded that such regenera-
tion is “an expected development, not a failure of ablation.”
Other findings included dense intrauterine adhesions, total
obliteration of the cavity, and atrophic endometrium.
Similarly, Turnbull et al [9] were able to identify resid-
ual endometrium using magnetic resonance imaging in
94.9% of 59 subjects who had undergone endometrial
resection a mean of 34 months earlier. Of these, 22 subjects
(37%) were amenorrheic. These studies suggest that there
is a need to access the uterine cavity to evaluate the residual
or regenerated endometrium for diagnostic purposes after
endometrial ablation.
Other issues related to intracavity scarring following
endometrial ablation include cyclic pelvic pain from partial
or complete menstrual obstruction and hematometra, which
may occur months or years after the procedure [1]. Three
large retrospective studies by Shavell et al [10], Longinatti
et al [11], and Vilos et al [12] examined hysterectomy
specimens from women seeking additional care following
endometrial ablation. The indications for hysterectomy
were recurrent bleeding in 12% to 51%, cyclic pain in 20%
to 64%, and a combination of pain and bleeding in 23% to
Johns et al. PACE Trial on Hysteroscopic Access to Uterine Cavity 127938%. These occurrences have recently been termed late-
onset endometrial ablation failure. These manifestations,
characterized by either recurrent bleeding or cyclic pain,
have stimulated hysteroscopic attempts to recreate a cavity
space for diagnosis or therapy, thus avoiding hysterectomy
in patients desiring a less invasive option [13].
A 24-month feasibility trial by Thurkow et al produced
promising results in terms of reduction of menstrual bleed-
ing and continued satisfaction in 22 subjects who had
undergone water vapor ablation [14]. Eleven of these sub-
jects subsequently consented to hysteroscopic evaluation of
the endometrial cavity as part of the PACE pilot study a
mean of 4.1 years after the original procedure. In this pilot
study, hysteroscopic access to the cavity and diagnostic
assessment was possible in 82% (9/11) of subjects [15].
A few studies have been conducted to evaluate access to
the endometrial cavity after ablation. The methods of these
studies vary widely, making it difficult to draw direct and
meaningful comparisons with the findings from this study.
Leung et al [16] and Luo et al [17], however, collected data
on the menstrual status of subjects at the time of hysteros-
copy after endometrial ablation using other modalities.
They concluded that a greater degree of fibrosis and adhe-
sion formation was correlated with a better reduction in
menses after endometrial ablation. This is in contrast to the
findings of our study using water vapor ablation. The sub-
jects with amenorrhea had a high rate of uterine cavity
access with a low incidence of adhesion formation. There
was no correlation between bleeding status and uterine cav-
ity access/adhesions.
The results from the PACE study further demonstrate
that long-term access to the uterine cavity can be achieved
in women who had undergone water vapor endometrial
ablation 4 years prior. The majority of these women did not
have intrauterine adhesions, which permitted uterine cavity
access with visualization of the cornua and ostia. In most
women, Pipelle biopsy and placement of an IUD were pro-
jected to be feasible. Moreover, menstrual bleeding status
was not correlated with uterine cavity access and the ability
to visualize the uterine cornua and ostia. Long-term effec-
tiveness and cavity access were consistent in subjects with
longer cavities (up to 12 cm), uterine myomas (FIGO type
II−VI up to 4 cm), and/or intratubal contraceptive inserts,
each of which has been traditionally excluded from endo-
metrial ablation treatment.
Results from the pivotal trial [3] revealed that water
vapor endometrial ablation is safe and provides effective
long-term (over 3 years) bleeding reduction. Moreover, the
results of this study, in combination with the PACE pilot
study [15], show that water vapor ablation does not com-
monly compromise a clinician’s ability to access the uterine
cavity hysteroscopically for diagnosis or treatment.
The strengths of this study include its prospective nature.
Regardless of the outcome of their ablation procedure, all
pivotal subjects at each participating site were invited to par-
ticipate in the current study, eliminating any bias based onthe results of the original ablation. In addition, an accepted
peer-reviewed scale was used to characterize uterine cavity
adhesions. Analysis by a single experienced independent
reviewer added objectivity and uniformity to the analysis.
Limitations of the study include its single-arm, observa-
tional design. In addition, the feasibility of a blind biopsy or
IUD placement is strictly a projection made by the indepen-
dent reviewer. Furthermore, although the inclusion of Pipelle
endometrial biopsy introduces a first-line endometrial sam-
pling technique familiar to practitioners and accepted by
patients in an office setting, the limitations of this sampling
method, especially in patients who have undergone prior
endometrial ablation, are acknowledged [18]. Data on the
need for anesthesia, type of analgesia used, and patient com-
fort during the hysteroscopic procedure were not collected in
this study. Finally, follicle-stimulating hormone levels were
not measured in the study subjects at baseline, and it is possi-
ble that undiagnosed menopause with onset after the ablation
procedure could confound findings on whether a subject was
amenorrheic because of the effect of the ablation treatment
or because of menopause. However, the authors prospec-
tively followed the bleeding status and noted the stability of
reported menstrual effect from 12 months to 4 years after
procedure in most subjects (Fig. 2).
In conclusion, it is clear that long-term access to the uterine
cavity is an important consideration in the ongoing care of
women who choose endometrial ablation for the treatment of
heavy menstrual bleeding. Future research in the form of pro-
spective, randomized, comparative trials would be useful to
understand long-term outcomes among various endometrial
ablation modalities. The ultimate goal should be the opportu-
nity to offer ongoing minimally invasive diagnosis and treat-
ment options to women who choose endometrial ablation.
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